Logo
x

Search

Subscribe Now

unresectable

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or...

  • June 4, 2021
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelio...

  • June 3, 2021
ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...

  • May 28, 2021
BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC

BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or M...

  • April 9, 2021
Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

  • March 24, 2021
Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

  • February 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.